Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

BeOne Medicines Publishes Clinical Trial Portfolio Presentation

By Public Technologies
  • BeOne Medicines published its Q3 2026 clinical trials portfolio presentation.
  • Sonrotoclax holds U.S. approval for relapsed or refractory mantle cell lymphoma; an EU submission has been accepted.
  • Phase 3 trials of sonrotoclax in relapsed or refractory blood cancers remain enrolling.
  • Tacabrutideg’s Phase 3 trial against pirtobrutinib in relapsed or refractory CLL/SLL is enrolling 500 patients.
  • New pivotal programs include B7-H4 ADC in first-line ovarian cancer maintenance and GPC3-targeted therapy in second-line or later liver cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.